Richard Buurman, MD
Family Medicine · Crossville, TNNPI 1467544148
Payments from drug & device makers
Across 317 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Amgen$379
- Lilly USA, LLC$318
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$292
- AbbVie$216
- Novartis$203
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,85499%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 85 | $1,323 |
| Amgen(2 entities) | 24 | $379 |
| Lilly USA, LLC | 18 | $318 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $292 |
| AbbVie(2 entities) | 11 | $216 |
| Novartis | 22 | $203 |
| Abbott | 11 | $190 |
| Bayer | 11 | $187 |
| Astellas Pharma US Inc | 10 | $185 |
| Pfizer | 14 | $181 |
| Exact Sciences | 8 | $114 |
| Sumitomo Pharma America, Inc. | 6 | $113 |
| Merck | 6 | $100 |
| GSK | 7 | $90 |
| Eisai Inc. | 6 | $88 |
| Sunovion Pharmaceuticals Inc. | 7 | $86 |
| Lundbeck LLC | 4 | $80 |
| Boston Scientific | 3 | $73 |
| Johnson & Johnson | 4 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $58 |
| Boehringer Ingelheim | 3 | $56 |
| Esperion Therapeutics, Inc. | 3 | $50 |
| Edwards Lifesciences | 2 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Nevro Corp. | 2 | $44 |
| AstraZeneca | 3 | $44 |
| Inspire Medical Systems, Inc. | 1 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Medtronic(2 entities) | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $28 |
| Ascensia Diabetes Care US Inc. | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Seqirus USA Inc | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Averitas Pharma Inc. | 1 | $15 |
| Biogen | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $10 |
How this compares
$4,913 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 154 | $168,678 |
| JardianceEmpagliflozin | 53 | $78,753 |
| OzempicSemaglutide | 53 | $62,390 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $54,632 |
| XareltoRivaroxaban | 51 | $38,540 |
| JanuviaSitagliptin Phosphate | 23 | $37,337 |
| MounjaroTirzepatide | 20 | $30,920 |
| MyrbetriqMirabegron | 41 | $20,734 |
| VraylarCariprazine Hcl | 16 | $20,441 |
| FarxigaDapagliflozin Propanediol | 23 | $19,168 |
| EntrestoSacubitril/Valsartan | 12 | $18,356 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $14,831 |
| Spiriva HandihalerTiotropium Bromide | 11 | $13,838 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $13,533 |
| Repatha SureclickEvolocumab | 19 | $13,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $181 | $168,678154 claims |
| Boehringer IngelheimJardiance | $56 | $78,75353 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $90 | $74,37983 claims |
| Novo NordiskOzempic | $1,323 | $62,39053 claims |
| Johnson & JohnsonXarelto | $65 | $38,54051 claims |
| MerckJanuvia | $100 | $37,33723 claims |
| Lilly USA, LLCMounjaro | $318 | $30,92020 claims |
| AbbVieVraylar, Linzess | $216 | $30,78035 claims |
| AstraZenecaFarxiga, Symbicort | $44 | $24,39247 claims |
| Astellas Pharma US IncMyrbetriq | $185 | $20,73441 claims |
| NovartisEntresto | $203 | $18,35612 claims |
| Sanofi-aventis U.S. LLCLantus | $58 | $4,78344 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Crossville
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.